

**Supplemental Table 1:** Characteristics for prevalent (n=73) and incident (n=29) SLE patients included in the study at baseline.

	Prevalent	Incident
<b>Demographics</b>	<b>Mean <math>\pm</math> SD or n (%)</b>	
Age, years	48.68 $\pm$ 13.42	53.24 $\pm$ 16.97
Gender, Female	63 (86)	22 (76)
BMI	25.44 $\pm$ 4.82	25.62 $\pm$ 4.32
Disease duration, years	14.35 $\pm$ 12.08	0.32 $\pm$ 0.31
APS	12 (16)	4 (15)
<b>ACR criteria n=99</b>	<b>n (%)</b>	
Arthritis	56 (78)	23 (85)
Thrombocytopenia	21 (29)	3 (11)
Malar rash	25 (35)	1 (4)
Discoid rash	15 (21)	3 (11)
Hemolytic anemia	4 (6)	0 (0)
Renal disorder	23 (32)	2 (7)
<b>Medication n=102</b>	<b>n (%)</b>	
NSAID/ Cox-II Inhibitors	16 (22)	9 (31)
Antimalarials	58 (79)	19 (66)
Immunomodulators	66 (92)	20 (74)
Methotrexate	13 (18)	3 (10)
Biologic agents	0 (0)	7 (10)
Steroids	16 (22)	6 (21)
Other DMARD	21 (29)	7 (24)
Prednisone	15 (21)	6 (21)
<b>Clinical characteristics</b>	<b>Mean <math>\pm</math> SD or n (%)</b>	
SLEDAI	2.75 $\pm$ 3.65	3.93 $\pm$ 3.79
Platelet, 10 <sup>9</sup> /L	224.57 $\pm$ 74.62	233.72 $\pm$ 76.56
MPV, fL	8.95 $\pm$ 1.33	8.83 $\pm$ 1.42
Hemoglobin, g/L	129.19 $\pm$ 13.43	129.69 $\pm$ 9.06
CRP, mg/L	3.82 $\pm$ 5.30	5.87 $\pm$ 10.29
ESR, mm/hour	10.42 $\pm$ 11.00	20.93 $\pm$ 23.92
Lupus anticoagulant	9 (14)	2 (8)
Anti-cardiolipin IGG	equivocal abnormal	2 (3) 4 (17)
Anti-cardiolipin IGM	equivocal abnormal	1 (2) 8 (13)
anti- $\beta_2$ GPI IGG	abnormal	6 (10)
anti- $\beta_2$ GPI IGM	abnormal	12 (19)
<b>Cardiovascular damages</b>	<b>Mean <math>\pm</math> SD or n (%)</b>	
History of thrombosis		
Venous	6 (8)	1 (3)
Arterial	1 (1)	3 (10)
Microcirculation	1 (1)	0 (0)
Plaque	22/55 (47)	9/17 (60)

---

CIMT, mm	0.59 ± 0.09 (30)	0.75 ± 0.21 (5)
----------	------------------	-----------------

---

ACR: American College of Rheumatology; APS: antiphospholipid syndrome;  $\beta_2$ GPI:  $\beta_2$  glycoprotein I; BMI: body mass index; CIMT: carotid intima-media thickness; CRP: C reactive protein; DMARD: Disease Modifying Anti Rheumatic Drug; ESR: erythrocyte sedimentation rate; MPV: mean platelet volume; NSAID: nonsteroidal anti-inflammatory drug; SLEDAI: SLE disease activity index.

**Supplemental Table 2:** Comparison of SLE patients with low (n=46) and high (n=40) PS<sup>+</sup> REVs after the exclusion of SLE patients with APS.

<b>Demographic characteristics</b>		low	high	<i>P</i> <sub>value</sub>
Gender	Female	41 (89)	34 (85)	0.7481
Age, years		51.50 (41.00; 62.00)	49.50 (39.00; 59.00)	0.7073
Disease duration, years		8.53(0.76; 22.53)	3.58 (1.19; 16.00)	0.1556
Onset	Incident	15 (33)	10 (25)	0.4829
	Prevalent	31 (67)	30 (75)	
APS		0 (0)	0 (0)	
<b>Clinical characteristics</b>				
SLEDAI		2.00 (0.00; 6.00)	1.50 (0.00; 4.00)	0.1421
Platelet, 10 <sup>9</sup> /L		237.00 (195.00; 293.00)	213.50 (179.50; 251.50)	0.1464
MPV, fL		8.70 (7.80; 10.00)	8.80 (8.00; 9.50)	0.7821
Hemoglobin, g/L		129.00 (122.00; 136.00)	130.00 (122.00; 137.00)	0.6992
CRP, mg/L		2.90 (1.01; 3.42)	2.00 (1.00; 4.08)	0.9342
ESR, mm/hour		8.00 (4.00; 20.00)	6.00 (3.00; 17.00)	0.3838
Lupus anticoagulant	presence	1 (3)	1 (3)	1.0000
Anti-cardiolipin IGG	abnormal	2 (6)	7 (18)	0.1613
	equivocal	1 (3)	0 (0)	
Anti-cardiolipin IGM	abnormal	2 (6)	3 (8)	0.8186
	equivocal	1 (3)	0 (0)	
Anti-β <sub>2</sub> GP1 IGG	abnormal	0 (0)	3 (8)	0.2431
Anti-β <sub>2</sub> GP1 IGM	abnormal	3 (9)	5 (8)	0.7161
<b>Laboratory measurements</b>				
ATX, ng/mL		233.05 (194.30; 295.30)	289.48 (209.88; 408.73)	<b>0.0281</b>
PEVs, EVs/μL		2442 (1089; 5044)	4919 (3067; 8517)	<b>0.0009</b>
PS+ PEVs, EVs/μL		2130 (957; 4306)	4520 (2370; 7761)	<b>0.0009</b>
REVs, EVs/μL		711 (422; 1333)	4269 (3192; 7040)	<b>&lt;.0001</b>
<b>ACR criteria</b>				
Arthritis		34 (76)	33 (83)	0.5958
Thrombocytopenia		9 (20)	11 (28)	0.4521
Malar rash		16 (36)	7 (18)	0.0869
Discoid rash		10 (22)	7 (18)	0.7866
Hemolytic anemia		3 (7)	1 (3)	0.6186
Renal disorder		11 (24)	10 (25)	1.0000
<b>Cardiovascular damages</b>				
History of thrombosis		0 (0)	4 (10)	<b>0.0430</b>
<b>Medication</b>				
NSAID/ Cox-II Inhibitors		13 (28)	8 (20)	0.4544
Prednisone		7 (15)	9 (23)	0.4181
Immunomodulators		38 (84)	35 (88)	0.7624

Continuous variables are presented as median (Interquartile range),  $P_{value}$  based on Wilcoxon Mann Whitney Test. Categorical variables are presented as n (%),  $P_{value}$  based on Exact Pearson Chi Square Test.

**Supplemental Table 3:** Comparison of SLE patients with low (n=38) and high (n=64) PS<sup>+</sup> PEVs.

		PS <sup>+</sup> PEV		
<b>Demographic characteristics</b>		Low	High	<i>P</i> <sub>value</sub>
Gender	Female	33 (87)	52 (81)	0.5868
Age, years		52.00 (45.00; 62.00)	49.00 (39.00; 59.00)	0.2705
Disease duration, years		11.92 (3.39; 22.29)	3.80 (0.44; 15.65)	<b>0.0183</b>
Onset	Incident	10 (26)	19 (30)	0.8218
	Prevalent	28 (74)	45 (70)	
APS		8 (21)	8 (13)	0.2717
<b>Clinical characteristics</b>				
SLEDAI		2.00 (0.00; 4.00)	1.50 (0.00; 6.00)	0.4402
Platelet, 10 <sup>9</sup> /L		202.00 (179.00; 242.00)	232.50 (184.50; 289.00)	<b>0.0408</b>
MPV, fL		8.80 (8.10; 10.30)	8.80 (8.00; 9.50)	0.3242
Hemoglobin, g/L		129.00 (121.00; 138.00)	131.00 (123.00; 137.00)	0.3264
CRP, mg/L		1.90 (1.00; 3.00)	2.90 (1.00; 6.00)	0.1467
ESR, mm/hour		7.00 (2.00; 18.00)	7.00 (4.00; 17.00)	0.4916
Lupus anticoagulant	presence	4 (13)	7 (12)	1.0000
Anti-cardiolipin IGG	abnormal	2 (7)	11 (19)	0.0539
	equivocal	2 (7)	0 (0)	
Anti-cardiolipine IGM	abnormal	5 (18)	7 (12)	0.2258
	equivocal	1 (4)	0 (0)	
Anti-β <sub>2</sub> GP1 IGG	abnormal	3 (11)	5 (8)	1.0000
Anti-β <sub>2</sub> GP1 IGM	abnormal	5 (18)	12 (17)	1.0000
<b>Laboratory measurements</b>				
ATX, ng/mL		222.50 (178.10; 265.75)	283.95 (209.45; 364.85)	<b>0.0054</b>
PEVs, EVs/μL		1101 (546; 1987)	5415 (4151; 8329)	<b>&lt;.0001</b>
REVs, EVs/μL		1098 (558; 1878)	3349 (1220; 6235)	<b>0.0005</b>
PS+ REVs, EVs/μL		309 (68; 1179)	1534 (271; 2612)	<b>0.0006</b>
<b>ACR criteria</b>				
Arthritis		24 (69)	55 (86)	0.0648
Thrombocytopenia		11 (69)	13 (20)	0.2303
Malar rash		10 (29)	16 (25)	0.8119
Discoid rash		8 (23)	10 (16)	0.4195
Hemolytic anemia		2 (6)	2 (3)	0.6126
Renal disorder		10 (29)	15 (23)	0.6319
<b>Cardiovascular damages</b>				
History of thrombosis		7 (18)	5 (8)	0.1234
<b>Medication</b>				
NSAID/ Cox-II Inhibitors		12 (32)	13 (20)	0.2375
Prednisone		6 (16)	11 (23)	0.4511
Immunomodulators		33 (94)	53 (83)	0.1299

Continuous variables are presented as median (Interquartile range),  $P_{value}$  based on Wilcoxon Mann Whitney Test. Categorical variables are presented as n (%),  $P_{value}$  based on Exact Pearson Chi Square Test.